The Impact of Royalty Contract Revision in a Multistage Strategic R&D Alliance

References

• Anderson EG, Davis-Blake A, Erzurumlu SS, Joglekar NR, Parker GG, Loch C, Kavadias S. The effects of outsourcing, offshoring, and distributed product development organization on coordinating the NPD process. Handbook of New Product Development Management (2007) (Butterworth Heinemann, Burlington, MA) 259–290Google Scholar
• Bhaskaran S, Krishnan V. Effort, revenue, and cost sharing mechanisms for collaborative new product development. Management Sci. (2009) 55(7):1152–1169Link, Google Scholar
• Bhattacharya S, Krishnan V, Mahajan V. Managing new product definition in highly dynamic environments. Management Sci. (1998) 44(11):S50–S64Link, Google Scholar
• Bolton P, Dewatripont M. Contract Theory (2005) (MIT Press, Cambridge, MA) Google Scholar
• Chao R, Kavadias S. A theoretical framework for managing new product development portfolio: When and how to use strategic buckets. Management Sci. (2008) 54(5):907–921Link, Google Scholar
• Chao R, Kavadias S, Gaimon C. Revenue driven resource allocation: Funding authority, incentives, and new product development portfolio management. Management Sci. (2009) 55(9):1556–1569Link, Google Scholar
• Che Y, Gale I. Optimal design of research contests. Amer. Econom. Rev. (2003) 93(3):646–671Crossref, Google Scholar
• Crama P, De Reyck B, Degraeve Z. Milestone payments or royalties? Contract design for R&D licensing. Oper. Res. (2008) 56(6):1539–1552Link, Google Scholar
• Drug Discovery & Development Alseres Pharmaceuticals enters agreement to amend Cethrin license to lower milestone payments and royalty rates. (2008) May 14Google Scholar
• Erat S, Kavadias S, Gaimon C. Licensing of component technologies. (2007) . Working paper, Georgia Institute of Technology, AtlantaGoogle Scholar
• Fudenberg D, Tirole J. Moral hazard and renegotiation in agency contracts. Econometrica (1990) 58(6):1279–1320Crossref, Google Scholar
• Fudenberg D, Tirole J. Game Theory (1991) (MIT Press, Cambridge, MA) Google Scholar
• Gallini NT, Wright BD. Technology transfer under asymmetric information. RAND J. Econom. (1990) 21(1):147–160Crossref, Google Scholar
• Global Business Insights Pharmaceutical strategic alliances. (2008) . Commercial research report, Global Business Insights, LondonGoogle Scholar
• Hart OD, Tirole J. Contract renegotiation and Coasian dynamics. Rev. Econom. Stud. (1988) 55(4):509–540Crossref, Google Scholar
• Jain S, Ramdas K. Up or out: New product positioning in an evolving technology environment. Production Oper. Management (2005) 14(3):362–376Crossref, Google Scholar
• Kamien MI, Tauman Y. Fees versus royalties and the private value of a patent. Quart. J. Econom. (1986) 101:471–492Crossref, Google Scholar
• Kaplan SN, Stromberg P. Characteristics, contracts, and actions: Evidence from venture capitalist analyses. J. Finance (2004) 59(5):2177–2210Crossref, Google Scholar
• Kim J. Alliance governance and technological performance: Some evidence from biotechnology alliances. Indust. Corporate Change (2011) 20(4):969–990Crossref, Google Scholar
• Krishnan V, Loch C. A retrospective look at Production and Operations Management articles on new product development. Production Oper. Management (2005) 14(4):433–441Crossref, Google Scholar
• Krishnan V, Ulrich KT. Product development decisions: A review of the literature. Management Sci. (2001) 47(1):1–21Link, Google Scholar
• Laffont J-J, Tirole J. Adverse selection and renegotiation in procurement. Rev. Econom. Stud. (1990) 57(4):597–625Crossref, Google Scholar
• Lerner J, Murray TH, Mehlman MJ. Strategic alliances and technology licensing in biotechnology. Encyclopedia of Ethical, Legal, and Policy Issues in Biotechnology (2000) (John Wiley & Sons, New York) 1069–1079Google Scholar
• Loch CH, Kavadias S. Handbook of New Product Development Management (2007) (Butterworth Heinemann-Elsevier, Burlington, MA) Crossref, Google Scholar
• Ligand Pharmaceuticals Ligand exercises first option to buy down ONTAK(R) royalities. (2005) . News release, January 7Google Scholar
• Mason R, Savva N, Scholtes S. The economics of licensing contracts. Nature Biotechnology (2008) 26(8):855–857Google Scholar
• Medical News Today Bristol-Myers Squibb and ZymoGenetics enter global collaboration on novel hepatitis C compound. (2009) January 12Google Scholar
• Medivir Medivir receives $45 million from Meda for US rights for Xerese™. (2011) . News release, June 29Google Scholar
• Mihm J. Incentives in new product development projects and the role of target costing. Management Sci. (2010) 56(8):1324–1344Link, Google Scholar
• Nöldeke G, Schmidt KM. Option contracts and renegotiation: A solution to the hold-up problem. RAND J. Econom. (1995) 26(2):163–179Crossref, Google Scholar
• Pisano GP. The R&D boundaries of the firm: An empirical analysis. Admin. Sci. Quart. (1990) 35(1):153–176Crossref, Google Scholar
• Plambeck EL, Taylor TA. Implications of renegotiation for optimal contract flexibility and investment. Management Sci. (2007) 53(12):1872–1886Link, Google Scholar
• Savva N, Scholtes S. Double or quits: Opt out options in pharmaceutical R&D contracts. (2009) . Working paper, London Business School, LondonGoogle Scholar
• Sommer SC, Loch CH. Selectionism and learning in projects with complexity and unforeseeable uncertainty. Management Sci. (2004) 50(10):1334–1347Link, Google Scholar
• Sommer SC, Loch CH. Incentive contracts in projects with unforeseeable uncertainty. Production Oper. Management (2009) 18(2):185–196Crossref, Google Scholar
• Terwiesch C, Loch CH. Collaborative prototyping and the pricing of custom-designed products. Management Sci. (2004) 50(2):145–158Link, Google Scholar
• Xiao W, Xu Y. The impact of royalty contract revision in a multistage strategic R&D alliance (unabbreviated). (2011) . Working paper, New York University, New YorkGoogle Scholar